Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Langdon

Showing results (61-70 of 180) with videos related to

Pageof 18
Sort By:
Toxicology|February 1, 1985
Studies on the toxicity of the antitumour agent N-methylformamide in miceS P Langdon, D Chubb, A Gescher, et al.
International Journal of Cancer|September 27, 2005
Comparison of strategies targeting Raf-1 mRNA in ovarian cancerPeter Mullen, Fiona McPhillips, Brett P Monia, et al.
Biochemical Pharmacology|August 25, 1995
Characterization of the deamidase enzyme responsible for the metabolism of the anticancer peptide: H-Arg-D-Trp-NmePhe-D-Trp-Leu-Met-NH2D A Jones, J Cummings, S P Langdon, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|November 12, 2016
Kinetic modelling of in vitro data of PI3K, mTOR1, PTEN enzymes and on-target inhibitors Rapamycin, BEZ235, and LY294002Alexey Goltsov, Ghassan Tashkandi, Simon P Langdon, et al.
Cellular Signalling|December 24, 2022
Variation in IL6ST cytokine family function and the potential of IL6 trans-signalling in ERα positive breast cancer cellsDuniya Mosly, Kenneth MacLeod, Nicholas Moir, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 28, 2009
Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastasesS J Aitken, J S Thomas, S P Langdon, et al.
Molecular Endocrinology (Baltimore, Md.)|August 2, 2007
Progressive loss of estrogen receptor alpha cofactor recruitment in endocrine resistanceCatherine Naughton, Kenneth MacLeod, Barbara Kuske, et al.
Cellular Signalling|October 15, 2011
Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibitionAlexey Goltsov, Dana Faratian, Simon P Langdon, et al.
Cellular Signalling|October 19, 2010
Compensatory effects in the PI3K/PTEN/AKT signaling network following receptor tyrosine kinase inhibitionAlexey Goltsov, Dana Faratian, Simon P Langdon, et al.
Oxidative Medicine and Cellular Longevity|January 16, 2016
NRF2 Regulates HER2 and HER3 Signaling Pathway to Modulate Sensitivity to Targeted ImmunotherapiesHilal S Khalil, Simon P Langdon, Ibrahim H Kankia, et al.
Pageof 18

Showing results (61-70 of 180) with videos related to

Sort By:
Pageof 18
Toxicology|February 1, 1985
Studies on the toxicity of the antitumour agent N-methylformamide in miceS P Langdon, D Chubb, A Gescher, et al.
International Journal of Cancer|September 27, 2005
Comparison of strategies targeting Raf-1 mRNA in ovarian cancerPeter Mullen, Fiona McPhillips, Brett P Monia, et al.
Biochemical Pharmacology|August 25, 1995
Characterization of the deamidase enzyme responsible for the metabolism of the anticancer peptide: H-Arg-D-Trp-NmePhe-D-Trp-Leu-Met-NH2D A Jones, J Cummings, S P Langdon, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|November 12, 2016
Kinetic modelling of in vitro data of PI3K, mTOR1, PTEN enzymes and on-target inhibitors Rapamycin, BEZ235, and LY294002Alexey Goltsov, Ghassan Tashkandi, Simon P Langdon, et al.
Cellular Signalling|December 24, 2022
Variation in IL6ST cytokine family function and the potential of IL6 trans-signalling in ERα positive breast cancer cellsDuniya Mosly, Kenneth MacLeod, Nicholas Moir, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 28, 2009
Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastasesS J Aitken, J S Thomas, S P Langdon, et al.
Molecular Endocrinology (Baltimore, Md.)|August 2, 2007
Progressive loss of estrogen receptor alpha cofactor recruitment in endocrine resistanceCatherine Naughton, Kenneth MacLeod, Barbara Kuske, et al.
Cellular Signalling|October 15, 2011
Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibitionAlexey Goltsov, Dana Faratian, Simon P Langdon, et al.
Cellular Signalling|October 19, 2010
Compensatory effects in the PI3K/PTEN/AKT signaling network following receptor tyrosine kinase inhibitionAlexey Goltsov, Dana Faratian, Simon P Langdon, et al.
Oxidative Medicine and Cellular Longevity|January 16, 2016
NRF2 Regulates HER2 and HER3 Signaling Pathway to Modulate Sensitivity to Targeted ImmunotherapiesHilal S Khalil, Simon P Langdon, Ibrahim H Kankia, et al.
Pageof 18